Free Trial

Revvity Inc. $RVTY Shares Bought by Aberdeen Group plc

Revvity logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Aberdeen Group sharply increased its Revvity stake by 6,958.7% in the third quarter, adding 340,211 shares to reach 345,100 shares valued at about $52.8 million.
  • Revvity reported quarterly earnings of $1.38 per share, above the $1.30 consensus estimate, while revenue of $728.9 million beat forecasts and rose 4.3% year over year.
  • Analysts’ consensus rating is Hold, with a $133.86 average price target; the company also declared a quarterly dividend of $0.07 per share.
  • MarketBeat previews the top five stocks to own by December 1st.

Aberdeen Group plc grew its stake in shares of Revvity Inc. (NYSE:RVTY - Free Report) by 6,958.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 345,100 shares of the company's stock after purchasing an additional 340,211 shares during the period. Aberdeen Group plc owned approximately 0.31% of Revvity worth $52,762,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of RVTY. Pillar Financial Advisors LLC purchased a new position in shares of Revvity during the third quarter valued at approximately $29,000. Heritage Family Offices LLP bought a new position in shares of Revvity during the third quarter valued at $37,000. Global Retirement Partners LLC purchased a new position in shares of Revvity in the 2nd quarter worth about $51,000. Root Financial Partners LLC purchased a new position in shares of Revvity in the 3rd quarter worth about $64,000. Finally, EverSource Wealth Advisors LLC boosted its stake in Revvity by 17.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 749 shares of the company's stock worth $66,000 after purchasing an additional 109 shares in the last quarter. 86.65% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Maxwell Krakowiak sold 1,631 shares of the stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $144.53, for a total value of $235,728.43. Following the completion of the sale, the insider directly owned 14,781 shares of the company's stock, valued at approximately $2,136,297.93. This represents a 9.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Tajinder Vohra sold 7,330 shares of the firm's stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the sale, the insider owned 6,635 shares in the company, valued at approximately $934,738.80. The trade was a 52.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 9,045 shares of company stock valued at $1,281,439. 0.85% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages recently commented on RVTY. TD Cowen increased their price objective on shares of Revvity from $175.00 to $185.00 and gave the company a "buy" rating in a research report on Wednesday, November 4th. JPMorgan Chase & Co. upped their target price on shares of Revvity from $155.00 to $160.00 and gave the company a "neutral" rating in a research note on Wednesday, November 4th. Evercore reiterated an "outperform" rating on shares of Revvity in a research note on Wednesday, August 5th. Bank of America reissued a "neutral" rating on shares of Revvity in a report on Wednesday, November 4th. Finally, Weiss Ratings upgraded shares of Revvity from a "hold (c)" rating to a "hold (c+)" rating in a research report on Wednesday. Six analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $133.86.

Get Our Latest Stock Report on Revvity

Revvity Stock Up 0.1%

RVTY opened at $154.60 on Monday. The company has a current ratio of 2.65, a quick ratio of 2.10 and a debt-to-equity ratio of 0.36. Revvity Inc. has a 1-year low of $81.22 and a 1-year high of $171.74. The company has a market capitalization of $17.26 billion, a PE ratio of 68.41, a PEG ratio of 2.70 and a beta of 1.08. The firm's 50 day simple moving average is $150.48 and its two-hundred day simple moving average is $114.30.

Revvity (NYSE:RVTY - Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.08. Revvity had a return on equity of 8.64% and a net margin of 8.61%. The company had revenue of $728.90 million for the quarter, compared to the consensus estimate of $694.73 million. During the same period in the previous year, the business earned $1.18 earnings per share. Revvity's quarterly revenue was up 4.3% compared to the same quarter last year. As a group, equities analysts forecast that Revvity Inc. will post 5.42 EPS for the current year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 12th. Stockholders of record on Friday, January 22nd will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, January 22nd. Revvity's payout ratio is presently 12.39%.

About Revvity

(Free Report)

Revvity, Inc. develops and supplies products and services for life sciences research and clinical diagnostics. Its offerings include instruments, reagents, software and related services used by pharmaceutical and biotechnology companies, academic and government research institutions, hospitals and clinical laboratories. The company's work spans areas such as drug discovery and development, genetic testing, newborn screening and other diagnostic applications. Its technologies help researchers and healthcare providers analyze biological samples and generate information used in research and patient care.

See Also

Want to see what other hedge funds are holding RVTY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revvity Inc. (NYSE:RVTY - Free Report).

Institutional Ownership by Quarter for Revvity (NYSE:RVTY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Revvity Right Now?

Before you consider Revvity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revvity wasn't on the list.

While Revvity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines